Sunitinib (SUN) is a multi-targeted tyrosine kinase inhibitor that was recently approved for the treatment of gastrointestinal tract and renal cancers. To date, very little is known about the effects of SUN on the expression of hepatic and renal xenobiotic-metabolizing enzymes (XMEs) and transporters. The present study was designed to investigate the capacity of chronic SUN treatment to modulate the mRNA and protein expression levels of phase I cytochrome P450 (CYP), phase II conjugating enzymes, and phase III transporters in rat liver and kidneys. For this purpose, SUN (25, 50 and 100 mg/kg) was injected IP into Wistar albino rats for 4 weeks; thereafter, the mRNA and protein expression levels of several XMEs and transporters were determined by RT-PCR and Western blot analysis, respectively. Real-time PCR analysis showed that SUN significantly induced the hepatic and renal CYP1A1, 1A2, 1B1, 2E1 and 4F4, whereas it inhibited CYP2C11 and 4A2. Furthermore, SUN specifically induced renal, but not hepatic, CYP2J3 and 3A2, while it induced only hepatic CYP4A1. With regard to phase II, SUN induced hepatic GSTA1 and UGT1A and renal NQO1 and UGT1A mRNA levels, whereas it inhibited renal GST1A expression. On the other hand, both renal and hepatic P-gp, MRP2 and BCRP transporters were significantly induced by SUN at the mRNA and protein expression levels. Importantly, these differential effects were associated with changes in oxidative stress genes and lipid peroxidation levels. In conclusion, SUN can serve as XME and transporters modulator, which potentially may counteract the efficacy of the treatment, adverse reactions and drug interactions in SUN treatment.Xenobiotic-metabolizing systems include phase I cytochrome P450 (CYP) oxidative enzymes, phase II conjugative enzyme systems and phase III transporters [1]. The mammalian CYP1, 2 and 3 families are single polypeptide membrane-bound haem proteins that play an essential role in the oxidative metabolism of a great variety of xenobiotic and endogenous compounds resulting in the formation of more water-soluble and less toxic metabolites [2]. On the other hand, phase II conjugative enzymes such as NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST) and uridine diphosphate glucuronosyltransferase (UGT) catalyse conjugation reactions necessary for xenobiotic metabolism and/or further metabolism of phase I enzyme products [1]. Thus, these enzymes play an essential role in the detoxification and elimination of xenobiotics and carcinogenic metabolites [1]. In 1992, Ishikawa first proposed a new concept of the phase III xenobiotic-metabolizing system known as transporters that play important roles in drug disposition, therapeutic efficacy and adverse drug reactions [3]. Many of these transporters, such as P-glycoprotein (P-gp), multi-drug resistance-associated protein (MRP) and breast cancer resistant protein (BCRP), have been characterized and are expressed in epithelia of the intestine, liver and kidney [4,5]. Thus, induction or inhibition of thes...